ECONOMIC BURDEN OF SCHIZOPHRENIA IN CHINA- A LITERATURE REVIEW
Author(s)
Jia Y1, Cheng X2, Aballea S3, Dorey J3, Toumi M4
1Shenyang Pharmaceutical University, Shenyang, China, 2Creativ-Ceutical, Hong Kong, Hong Kong, 3Creativ-Ceutical, Paris, France, 4Aix-Marseille University, Marseille, France
OBJECTIVES: This study aims to review the economic burden in patients with schizophrenia in China. METHODS: A literature review was performed through CNKI, Wangfang, CQVIP, EMBASE and Medline databases to identify cost studies published between 2007 and 2016. Original cost studies of schizophrenia were included containing inpatient or outpatient costs. Information related to direct medical costs (inpatient bed charges, treatment costs, healthcare professionals and examinations), non-medical costs (accommodation, food, and transportation costs), and indirect costs (loss of productivity for patients and time required from family members) were extracted. RESULTS:
Conference/Value in Health Info
2016-09, ISPOR Asia Pacific 2016, Singapore
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMH9
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health